Adding an experimental hormone mimic to tirzepatide pushed body mass reduction as high as 23.3% in a Lilly clinical trial, per NewsBytes.
Recap by typeshit. Full story at NewsBytes.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Novo Nordisk's newest Wegovy injection puts fresh pressure on rivals in the race to lead obesity treatment, The Times reports.
A new survey points to a hard money choice for some Americans: paying for Ozempic or putting that cash toward retirement. NewsNation has the numbers.
Loading…